良性前列腺梗阻微创手术功能与性功能结局的系统综述与汇总分析
该系统综述与汇总分析纳入24项研究,评估Rezūm、UroLift、iTind、TPLA和Optilume等微创手术治疗良性前列腺梗阻的功能与性功能结局。多数微创手术在12个月时IPSS和Qmax改善≥50%,QoL改善≥1分,射精障碍率TPLA为5%、Rezūm为3%、iTIND为1%、UroLift和Optilume为0%。作者据此提出手术成功的定义。
要点
- 多数MIST在12个月时IPSS和Qmax改善≥50%,QoL改善≥1分。
- 无射精率:TPLA 5%、Rezūm 3%、iTIND 1%、UroLift和Optilume 0%。
- 提出手术成功定义:IPSS、Qmax、QoL改善≥50%且无严重并发症并保留性功能。
核心结论
- MISTs是良性前列腺梗阻有前景的治疗工具,可有效缓解症状并保留性功能。
研究设计与样本
- 系统综述与汇总分析,检索PubMed、Scopus、Web of Science和Cochrane Library(2025年2月),纳入24项随机对照试验和前瞻性研究。
主要发现
- 多数MISTs在12个月时IPSS和Qmax改善≥50%,QoL改善≥1分。
- 无射精率:TPLA 5%、Rezūm 3%、iTIND 1%、UroLift和Optilume 0%。
- 并发症和再治疗率低,但随访时间报告不一致且主要限于24个月。
关键数值与推荐
- 手术成功定义:IPSS降低≥50%、Qmax改善≥50%、QoL改善≥50%(或≥1分)、无术中并发症和Clavien-Dindo≥III级术后并发症、保留勃起功能和顺行射精。
临床怎么用
- 临床可根据手术成功定义综合评估MISTs的疗效与性功能保护。
- 选择MISTs时应考虑不同术式的射精障碍发生率差异。
局限性
- 随访时间报告不一致且主要限于24个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Minimally invasive surgical treatments (MISTs) for benign prostatic obstruction have been developed with the aim of providing superior symptom relief in comparison to pharmacological treatment, while minimizing the impact on sexual function. The aim of our study was to assess key MIST outcomes and to propose a definition of procedural success. METHODS: A systematic literature search was conducted in February 2025 in the PubMed, Scopus, Web of Science, and Cochrane Library databases. The protocol, which follows the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and PICOS (Population, Intervention, Comparator, Outcomes, Study design) criteria, was registered on PROSPERO as CRD42024543361. The review focused on randomized controlled trials and prospective studies evaluating surgical and functional outcomes of MISTs (Rezūm, UroLift, temporary implantable nitinol device [iTind], transperineal laser ablation [TPLA], Optilume) for BPO. We assessed the risk of bias and graded the certainty of evidence from the articles included. Pooled analyses were performed to compare perioperative and functional outcomes between study groups. KEY FINDINGS AND LIMITATIONS: The 24 studies included in the review found that most MISTs were effective, showing improvements at 12 mo of ≥50% in the International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax), and of ≥1 point for at quality of life (QoL) questionnaire. Anejaculation rates were 5% with TPLA, 3% with Rezūm, 1% with iTIND, and 0% with UroLift and Optilume. Complication and retreatment rates were low, although the follow-up duration was inconsistently reported and mainly limited to 24 mo. On the basis of these results, we propose a definition of procedural success that comprises achievement of all the following outcomes: IPSS reduction of ≥50%, Qmax improvement of ≥50%, QoL improvement of ≥50% (or ≥1 point), the absence of intraoperative complications and Clavien-Dindo grade ≥III postoperative complications, and preservation of erectile function and of antegrade ejaculation. CONCLUSIONS AND CLINICAL IMPLICATIONS: MISTs represent a promising tool for benign prostatic obstruction management and provide effective symptom relief while preserving sexual function.
引用
- Franco A, Ditonno F, Manfredi C, et al. Systematic Review and Pooled Analysis of Functional and Sexual Outcomes of Minimally Invasive Surgical Treatments for Benign Prostatic Obstruction. Eur Urol. 2025. PMID: 40967932. doi:10.1016/j.eururo.2025.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。